Cargando…

Serological Studies Confirm the Novel Astrovirus HMOAstV-C as a Highly Prevalent Human Infectious Agent

Molecular identification of a microbe is the first step in determining its prevalence of infection and pathogenic potential. Detection of specific adaptive immune responses can provide insights into whether a microbe is a human infectious agent and its epidemiology. Here we characterized human anti-...

Descripción completa

Detalles Bibliográficos
Autores principales: Burbelo, Peter D., Ching, Kathryn H., Esper, Frank, Iadarola, Michael J., Delwart, Eric, Lipkin, W. Ian, Kapoor, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150362/
https://www.ncbi.nlm.nih.gov/pubmed/21829634
http://dx.doi.org/10.1371/journal.pone.0022576
_version_ 1782209538470969344
author Burbelo, Peter D.
Ching, Kathryn H.
Esper, Frank
Iadarola, Michael J.
Delwart, Eric
Lipkin, W. Ian
Kapoor, Amit
author_facet Burbelo, Peter D.
Ching, Kathryn H.
Esper, Frank
Iadarola, Michael J.
Delwart, Eric
Lipkin, W. Ian
Kapoor, Amit
author_sort Burbelo, Peter D.
collection PubMed
description Molecular identification of a microbe is the first step in determining its prevalence of infection and pathogenic potential. Detection of specific adaptive immune responses can provide insights into whether a microbe is a human infectious agent and its epidemiology. Here we characterized human anti-IgG antibody responses by luciferase immunoprecipitation systems (LIPS) against two protein fragments derived from the capsid protein of the novel HMOAstV-C astrovirus. While antibodies to the N-terminal fragment were not informative, the C-terminal capsid fragment of HMOAstV-C showed a high frequency of immunoreactivity with serum from healthy blood donors. In contrast, a similar C-terminal capsid fragment from the related HMOAstV-A astrovirus failed to show immunoreactivity. Detailed analysis of adult serum from the United Sates using a standardized threshold demonstrated HMOAstV-C seropositivity in approximately 65% of the samples. Evaluation of serum samples from different pediatric age groups revealed that the prevalence of antibodies in 6–12 month, 1–2 year, 2–5 year and 5–10 year olds was 20%, 23%, 32% and 36%, respectively, indicating rising seroprevalence with age. Additionally, 50% (11/22) of the 0–6 month old children showed anti-HMOAstV-C antibody responses, likely reflecting maternal antibodies. Together these results document human humoral responses to HMOAstV-C and validate LIPS as a facile and effective approach for identifying humoral responses to novel infectious agents.
format Online
Article
Text
id pubmed-3150362
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31503622011-08-09 Serological Studies Confirm the Novel Astrovirus HMOAstV-C as a Highly Prevalent Human Infectious Agent Burbelo, Peter D. Ching, Kathryn H. Esper, Frank Iadarola, Michael J. Delwart, Eric Lipkin, W. Ian Kapoor, Amit PLoS One Research Article Molecular identification of a microbe is the first step in determining its prevalence of infection and pathogenic potential. Detection of specific adaptive immune responses can provide insights into whether a microbe is a human infectious agent and its epidemiology. Here we characterized human anti-IgG antibody responses by luciferase immunoprecipitation systems (LIPS) against two protein fragments derived from the capsid protein of the novel HMOAstV-C astrovirus. While antibodies to the N-terminal fragment were not informative, the C-terminal capsid fragment of HMOAstV-C showed a high frequency of immunoreactivity with serum from healthy blood donors. In contrast, a similar C-terminal capsid fragment from the related HMOAstV-A astrovirus failed to show immunoreactivity. Detailed analysis of adult serum from the United Sates using a standardized threshold demonstrated HMOAstV-C seropositivity in approximately 65% of the samples. Evaluation of serum samples from different pediatric age groups revealed that the prevalence of antibodies in 6–12 month, 1–2 year, 2–5 year and 5–10 year olds was 20%, 23%, 32% and 36%, respectively, indicating rising seroprevalence with age. Additionally, 50% (11/22) of the 0–6 month old children showed anti-HMOAstV-C antibody responses, likely reflecting maternal antibodies. Together these results document human humoral responses to HMOAstV-C and validate LIPS as a facile and effective approach for identifying humoral responses to novel infectious agents. Public Library of Science 2011-08-04 /pmc/articles/PMC3150362/ /pubmed/21829634 http://dx.doi.org/10.1371/journal.pone.0022576 Text en Burbelo et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Burbelo, Peter D.
Ching, Kathryn H.
Esper, Frank
Iadarola, Michael J.
Delwart, Eric
Lipkin, W. Ian
Kapoor, Amit
Serological Studies Confirm the Novel Astrovirus HMOAstV-C as a Highly Prevalent Human Infectious Agent
title Serological Studies Confirm the Novel Astrovirus HMOAstV-C as a Highly Prevalent Human Infectious Agent
title_full Serological Studies Confirm the Novel Astrovirus HMOAstV-C as a Highly Prevalent Human Infectious Agent
title_fullStr Serological Studies Confirm the Novel Astrovirus HMOAstV-C as a Highly Prevalent Human Infectious Agent
title_full_unstemmed Serological Studies Confirm the Novel Astrovirus HMOAstV-C as a Highly Prevalent Human Infectious Agent
title_short Serological Studies Confirm the Novel Astrovirus HMOAstV-C as a Highly Prevalent Human Infectious Agent
title_sort serological studies confirm the novel astrovirus hmoastv-c as a highly prevalent human infectious agent
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150362/
https://www.ncbi.nlm.nih.gov/pubmed/21829634
http://dx.doi.org/10.1371/journal.pone.0022576
work_keys_str_mv AT burbelopeterd serologicalstudiesconfirmthenovelastrovirushmoastvcasahighlyprevalenthumaninfectiousagent
AT chingkathrynh serologicalstudiesconfirmthenovelastrovirushmoastvcasahighlyprevalenthumaninfectiousagent
AT esperfrank serologicalstudiesconfirmthenovelastrovirushmoastvcasahighlyprevalenthumaninfectiousagent
AT iadarolamichaelj serologicalstudiesconfirmthenovelastrovirushmoastvcasahighlyprevalenthumaninfectiousagent
AT delwarteric serologicalstudiesconfirmthenovelastrovirushmoastvcasahighlyprevalenthumaninfectiousagent
AT lipkinwian serologicalstudiesconfirmthenovelastrovirushmoastvcasahighlyprevalenthumaninfectiousagent
AT kapooramit serologicalstudiesconfirmthenovelastrovirushmoastvcasahighlyprevalenthumaninfectiousagent